Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17692777 | 0.86 | PTPN1 (0.38) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL12108764 | 0.85 | PTPN1 (0.38) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL24926544 | 0.83 | NSD2 (0.38) | LMNAHPGDHSD17B10MAOB | |
| SCHEMBL12108754 | 0.82 | PTPN1 (0.40) | PTPN1LMNAHPGDUSP2ALDH1A1 | |
| SCHEMBL12108776 | 0.81 | PTPN1 (0.39) | PTPN1LMNAHPGDUSP2ALDH1A1 | |
| SCHEMBL1300807 | 0.80 | PTPN1 (0.38) | PTPN1LMNAHPGDUSP2ALDH1A1 | |
| SCHEMBL17692768 | 0.80 | PTPN1 (0.40) | PTPN1LMNAHPGDTHRATHRB | |
| SCHEMBL20860622 | 0.80 | PTPN1 (0.40) | PTPN1LMNAHPGDPDK1PDK2 | |
| SCHEMBL12108773 | 0.79 | PTPN1 (0.38) | PTPN1LMNAHPGDUSP2ALDH1A1 | |
| SCHEMBL12109175 | 0.78 | PTPN1 (0.36) | PTPN1LMNAHPGDUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | PTPN1 385/4885LMNA 1638/4885HPGD 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.